CXCL1 and neoplasm: Moreover, PP2, a specific SFKs inhibitor mainly targeting Lck/Fyn and displaying anticancer activity [28, 29], abrogated the migration of CXCL1/LCN2 stimulated tumor cells (Fig. 6a and b).